Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force | Atrial Fibrillation | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
1.
January  CT, Wann  LS, Alpert  JS,  et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.  J Am Coll Cardiol. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022PubMedGoogle ScholarCrossref
2.
Go  AS, Hylek  EM, Phillips  KA,  et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.  JAMA. 2001;285(18):2370-2375. doi:10.1001/jama.285.18.2370PubMedGoogle ScholarCrossref
3.
Harris  K, Edwards  D, Mant  J.  How can we best detect atrial fibrillation?  J R Coll Physicians Edinb. 2012;42(suppl 18):5-22.PubMedGoogle ScholarCrossref
4.
Watson  T, Shantsila  E, Lip  GY.  Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited.  Lancet. 2009;373(9658):155-166. doi:10.1016/S0140-6736(09)60040-4PubMedGoogle ScholarCrossref
5.
Stroke Risk in Atrial Fibrillation Working Group.  Independent predictors of stroke in patients with atrial fibrillation: a systematic review.  Neurology. 2007;69(6):546-554. doi:10.1212/01.wnl.0000267275.68538.8dPubMedGoogle ScholarCrossref
6.
Dulli  DA, Stanko  H, Levine  RL.  Atrial fibrillation is associated with severe acute ischemic stroke.  Neuroepidemiology. 2003;22(2):118-123. doi:10.1159/000068743PubMedGoogle ScholarCrossref
7.
Lamassa  M, Di Carlo  A, Pracucci  G,  et al.  Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (the European Community Stroke Project).  Stroke. 2001;32(2):392-398. doi:10.1161/01.STR.32.2.392PubMedGoogle ScholarCrossref
8.
Lin  HJ, Wolf  PA, Kelly-Hayes  M,  et al.  Stroke severity in atrial fibrillation: the Framingham Study.  Stroke. 1996;27(10):1760-1764. doi:10.1161/01.STR.27.10.1760PubMedGoogle ScholarCrossref
9.
Benjamin  EJ, Blaha  MJ, Chiuve  SE,  et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee.  Heart disease and stroke statistics—2017 update: a report from the American Heart Association.  Circulation. 2017;135(10):e146-e603. doi:10.1161/CIR.0000000000000485PubMedGoogle ScholarCrossref
10.
Menke  J, Lüthje  L, Kastrup  A, Larsen  J.  Thromboembolism in atrial fibrillation.  Am J Cardiol. 2010;105(4):502-510. doi:10.1016/j.amjcard.2009.10.018PubMedGoogle ScholarCrossref
11.
Wolf  PA, Kannel  WB, McGee  DL, Meeks  SL, Bharucha  NE, McNamara  PM.  Duration of atrial fibrillation and imminence of stroke: the Framingham Study.  Stroke. 1983;14(5):664-667. doi:10.1161/01.STR.14.5.664PubMedGoogle ScholarCrossref
12.
Lin  HJ, Wolf  PA, Benjamin  EJ, Belanger  AJ, D’Agostino  RB.  Newly diagnosed atrial fibrillation and acute stroke: the Framingham Study.  Stroke. 1995;26(9):1527-1530. doi:10.1161/01.STR.26.9.1527PubMedGoogle ScholarCrossref
13.
Hannon  N, Sheehan  O, Kelly  L,  et al.  Stroke associated with atrial fibrillation—incidence and early outcomes in the North Dublin Population Stroke Study.  Cerebrovasc Dis. 2010;29(1):43-49. doi:10.1159/000255973PubMedGoogle ScholarCrossref
14.
U.S. Preventive Services Task Force. U.S. Preventive Services Task Force Procedure Manual, Appendix VI. https://www.uspreventiveservicestaskforce.org/Page/Name/methods-and-processes. Published 2015. Accessed May 17, 2017.
15.
DerSimonian  R, Laird  N.  Meta-analysis in clinical trials.  Control Clin Trials. 1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2PubMedGoogle ScholarCrossref
16.
Higgins  JP, Thompson  SG.  Quantifying heterogeneity in a meta-analysis.  Stat Med. 2002;21(11):1539-1558. doi:10.1002/sim.1186PubMedGoogle ScholarCrossref
17.
Higgins  JP, Thompson  SG, Deeks  JJ, Altman  DG.  Measuring inconsistency in meta-analyses.  BMJ. 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557PubMedGoogle ScholarCrossref
18.
Population Health Research Institute. Home-based screening for early detection of atrial fibrillation in primary care patients aged 75 years and older (SCREEN-AF) [NCT02392754]. ClinicalTrials.gov website. https://ClinicalTrials.gov/show/NCT02392754. Cited 2017. Accessed April 6, 2018.
19.
Halcox  JPJ, Wareham  K, Cardew  A,  et al.  Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study.  Circulation. 2017;136(19):1784-1794. doi:10.1161/CIRCULATIONAHA.117.030583PubMedGoogle ScholarCrossref
20.
Svennberg  E, Engdahl  J, Al-Khalili  F, Friberg  L, Frykman  V, Rosenqvist  M.  Mass screening for untreated atrial fibrillation: the STROKESTOP study.  Circulation. 2015;131(25):2176-2184. doi:10.1161/CIRCULATIONAHA.114.014343PubMedGoogle ScholarCrossref
21.
Friberg  L, Engdahl  J, Frykman  V, Svennberg  E, Levin  LÅ, Rosenqvist  M.  Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP).  Europace. 2013;15(1):135-140. doi:10.1093/europace/eus217PubMedGoogle ScholarCrossref
22.
Karolinska University Hospital. Systematic ECG screening for atrial fibrillation among 75 year old subjects in the region of Stockholm and Halland, Sweden [NCT01593553]. ClinicalTrials.gov website. https://ClinicalTrials.gov/show/NCT01593553. Accessed April 6, 2018.
23.
Fitzmaurice  DA, McCahon  D, Baker  J,  et al.  Is screening for AF worthwhile? stroke risk in a screened population from the SAFE study.  Fam Pract. 2014;31(3):298-302. doi:10.1093/fampra/cmu011PubMedGoogle ScholarCrossref
24.
Fitzmaurice  DA, Hobbs  FD, Jowett  S,  et al.  Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial.  BMJ. 2007;335(7616):383. doi:10.1136/bmj.39280.660567.55PubMedGoogle ScholarCrossref
25.
Mant  J, Fitzmaurice  DA, Hobbs  FD,  et al.  Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from Screening for Atrial Fibrillation in the Elderly (SAFE) trial.  BMJ. 2007;335(7616):380. doi:10.1136/bmj.39227.551713.AEPubMedGoogle ScholarCrossref
26.
Hobbs  FD, Fitzmaurice  DA, Mant  J,  et al.  A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over: the SAFE study.  Health Technol Assess. 2005;9(40):1-74. doi:10.3310/hta9400PubMedGoogle ScholarCrossref
27.
Swancutt  D, Hobbs  R, Fitzmaurice  D,  et al.  A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732].  BMC Cardiovasc Disord. 2004;4:12. doi:10.1186/1471-2261-4-12PubMedGoogle ScholarCrossref
28.
Morgan  S, Mant  D.  Randomised trial of two approaches to screening for atrial fibrillation in UK general practice.  Br J Gen Pract. 2002;52(478):373-374, 377-380.PubMedGoogle Scholar
29.
Petersen  P, Boysen  G, Godtfredsen  J, Andersen  ED, Andersen  B.  Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study.  Lancet. 1989;1(8631):175-179. doi:10.1016/S0140-6736(89)91200-2PubMedGoogle ScholarCrossref
30.
Singer  DE, Hughes  RA, Gress  DR,  et al; Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.  N Engl J Med. 1990;323(22):1505-1511. doi:10.1056/NEJM199011293232201PubMedGoogle ScholarCrossref
31.
Stroke Prevention in Atrial Fibrillation Study Group Investigators.  Preliminary report of the Stroke Prevention in Atrial Fibrillation study.  N Engl J Med. 1990;322(12):863-868. doi:10.1056/NEJM199003223221232PubMedGoogle Scholar
32.
 Stroke Prevention in Atrial Fibrillation study: final results.  Circulation. 1991;84(2):527-539. doi:10.1161/01.CIR.84.2.527PubMedGoogle ScholarCrossref
33.
Connolly  SJ, Laupacis  A, Gent  M, Roberts  RS, Cairns  JA, Joyner  C.  Canadian Atrial Fibrillation Anticoagulation (CAFA) study.  J Am Coll Cardiol. 1991;18(2):349-355. doi:10.1016/0735-1097(91)90585-WPubMedGoogle ScholarCrossref
34.
Ezekowitz  MD, Bridgers  SL, James  KE,  et al; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation.  N Engl J Med. 1992;327(20):1406-1412. doi:10.1056/NEJM199211123272002PubMedGoogle ScholarCrossref
35.
Sato  H, Ishikawa  K, Kitabatake  A,  et al; Japan Atrial Fibrillation Stroke Trial Group.  Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.  Stroke. 2006;37(2):447-451. doi:10.1161/01.STR.0000198839.61112.eePubMedGoogle ScholarCrossref
36.
Aguilar  MI, Hart  R.  Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.  Cochrane Database Syst Rev. 2005;(3):CD001927.PubMedGoogle Scholar
37.
Aguilar  M, Hart  R.  Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.  Cochrane Database Syst Rev. 2005;(4):CD001925.PubMedGoogle Scholar
38.
Hart  RG, Pearce  LA, Aguilar  MI.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.  Ann Intern Med. 2007;146(12):857-867. doi:10.7326/0003-4819-146-12-200706190-00007PubMedGoogle ScholarCrossref
39.
 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials.  Arch Intern Med. 1994;154(13):1449-1457. doi:10.1001/archinte.1994.00420130036007PubMedGoogle ScholarCrossref
40.
Atrial Fibrillation Investigators.  The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials.  Arch Intern Med. 1997;157(11):1237-1240. doi:10.1001/archinte.1997.00440320143013PubMedGoogle ScholarCrossref
41.
van Walraven  C, Hart  RG, Connolly  S,  et al; Atrial Fibrillation Investigators.  Effect of age on stroke prevention therapy in patients with atrial fibrillation.  Stroke. 2009;40(4):1410-1416. doi:10.1161/STROKEAHA.108.526988PubMedGoogle ScholarCrossref
42.
Tereshchenko  LG, Henrikson  CA, Cigarroa  J, Steinberg  JS.  Comparative effectiveness of interventions for stroke prevention in atrial fibrillation: a network meta-analysis  [published online May 20, 2016].  J Am Heart Assoc. 2016;5(5):e003206. doi:10.1161/JAHA.116.003206PubMedGoogle ScholarCrossref
43.
Coleman  CI, Sobieraj  DM, Winkler  S,  et al.  Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation.  Int J Clin Pract. 2012;66(1):53-63. doi:10.1111/j.1742-1241.2011.02809.xPubMedGoogle ScholarCrossref
44.
Mather  M. Fact sheet: aging in the United States. Population Reference Bureau website. https://www.prb.org/aging-unitedstates-fact-sheet/. Published 2016. Accessed May 16, 2017.
45.
Engdahl  J, Andersson  L, Mirskaya  M, Rosenqvist  M.  Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention.  Circulation. 2013;127(8):930-937. doi:10.1161/CIRCULATIONAHA.112.126656PubMedGoogle ScholarCrossref
46.
Turakhia  MP, Ullal  AJ, Hoang  DD,  et al.  Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF).  Clin Cardiol. 2015;38(5):285-292. doi:10.1002/clc.22387PubMedGoogle ScholarCrossref
47.
Bogun  F, Anh  D, Kalahasty  G,  et al.  Misdiagnosis of atrial fibrillation and its clinical consequences.  Am J Med. 2004;117(9):636-642. doi:10.1016/j.amjmed.2004.06.024PubMedGoogle ScholarCrossref
48.
Go  AS, Hylek  EM, Chang  Y,  et al.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?  JAMA. 2003;290(20):2685-2692. doi:10.1001/jama.290.20.2685PubMedGoogle ScholarCrossref
49.
Welton  NJ, McAleenan  A, Thom  HH,  et al.  Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis.  Health Technol Assess. 2017;21(29):1-236. doi:10.3310/hta21290PubMedGoogle ScholarCrossref
50.
Utrecht  UMC. Improving DEtection of Atrial fibriLlation in Primary Care With the MyDiagnostick (IDEAL-MD) [NCT02270151]. ClinicalTrials.gov website. https://ClinicalTrials.gov/show/NCT02270151. Cited 2017. Accessed April 6, 2018.
51.
Steinhubl  SR, Mehta  RR, Ebner  GS,  et al.  Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: the mHealth Screening To Prevent Strokes (mSToPS) trial.  Am Heart J. 2016;175:77-85. doi:10.1016/j.ahj.2016.02.011PubMedGoogle ScholarCrossref
52.
Uittenbogaart  SB, Verbiest-van Gurp  N, Erkens  PM,  et al.  Detecting and Diagnosing Atrial Fibrillation (D2AF): study protocol for a cluster randomised controlled trial.  Trials. 2015;16:478. doi:10.1186/s13063-015-1006-5PubMedGoogle ScholarCrossref
US Preventive Services Task Force
Evidence Report
August 7, 2018

Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force

Author Affiliations
  • 1RTI International–University of North Carolina at Chapel Hill Evidence-based Practice Center
  • 2Department of Medicine, University of North Carolina at Chapel Hill
  • 3Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill
  • 4RTI International, Research Triangle Park, North Carolina
  • 5Department of Family Medicine, University of North Carolina at Chapel Hill
JAMA. 2018;320(5):485-498. doi:10.1001/jama.2018.4190
Abstract

Importance  Atrial fibrillation is the most common arrhythmia and increases the risk of stroke.

Objective  To review the evidence on screening for nonvalvular atrial fibrillation with electrocardiography (ECG) and stroke prevention treatment in asymptomatic adults 65 years or older to inform the US Preventive Services Task Force.

Data Sources  MEDLINE, Cochrane Library, and trial registries through May 2017; references; experts; literature surveillance through June 6, 2018.

Study Selection  English-language randomized clinical trials (RCTs), prospective cohort studies evaluating detection rates of atrial fibrillation or harms of screening, and systematic reviews evaluating stroke prevention treatment. Eligible treatment studies compared warfarin, aspirin, or novel oral anticoagulants (NOACs) with placebo or no treatment. Studies were excluded that focused on persons with a history of cardiovascular disease.

Data Extraction and Synthesis  Dual review of abstracts, full-text articles, and study quality. When at least 3 similar studies were available, random-effects meta-analyses were conducted.

Main Outcomes and Measures  Detection of previously undiagnosed atrial fibrillation, mortality, stroke, stroke-related morbidity, and harms.

Results  Seventeen studies were included (n = 135 300). No studies evaluated screening compared with no screening and focused on health outcomes. Systematic screening with ECG identified more new cases of atrial fibrillation than no screening (absolute increase, from 0.6% [95% CI, 0.1%-0.9%] to 2.8% [95% CI, 0.9%-4.7%] over 12 months; 2 RCTs, n = 15 803), but a systematic approach using ECG did not detect more cases than an approach using pulse palpation (2 RCTs, n = 17 803). For potential harms, no eligible studies compared screening with no screening. Warfarin (mean, 1.5 years) was associated with a reduced risk of ischemic stroke (relative risk [RR], 0.32 [95% CI, 0.20-0.51]) and all-cause mortality (RR, 0.68 [95% CI, 0.50-0.93]) and with increased risk of bleeding (5 trials, n = 2415). Participants in treatment trials were not screen detected, and most had long-standing persistent atrial fibrillation. A network meta-analysis reported that NOACs were associated with a significantly lower risk of a composite outcome of stroke and systemic embolism (adjusted odds ratios compared with placebo or control ranged from 0.32-0.44); the risk of bleeding was increased (adjusted odds ratios, 1.4-2.2), but confidence intervals were wide and differences between groups were not statistically significant.

Conclusions and Relevance  Although screening with ECG can detect previously unknown cases of atrial fibrillation, it has not been shown to detect more cases than screening focused on pulse palpation. Treatments for atrial fibrillation reduce the risk of stroke and all-cause mortality and increase the risk of bleeding, but trials have not assessed whether treatment of screen-detected asymptomatic older adults results in better health outcomes than treatment after detection by usual care or after symptoms develop.

×